Expedited partner therapy for sexually transmitted infections

Current Opinion in Obstetrics and Gynecology

Volumn 24, Issue 5, 2012, Pages 299-304

  Hogben, Matthew ^a   Kidd, Sarah ^a   Burstein, Gale R ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

antimicrobial resistance; partner treatment; sexually transmitted disease infection; STD prevention programs

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; DOXYCYCLINE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; BEHAVIOR THERAPY; CHLAMYDIASIS; DRUG HYPERSENSITIVITY; DRUG INDICATION; EVIDENCE BASED PRACTICE; EXPEDITED PARTNER THERAPY; FEASIBILITY STUDY; GONORRHEA; HETEROSEXUALITY; HUMAN; INFECTION RATE; LEGAL ASPECT; NEISSERIA GONORRHOEAE; NONHUMAN; PATIENT COUNSELING; PATIENT REFERRAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REINFECTION; REVIEW; SINGLE DRUG DOSE; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES;

ANTI-INFECTIVE AGENTS; CONTACT TRACING; DRUG RESISTANCE, MICROBIAL; FEMALE; GONORRHEA; HUMANS; MALE; SEXUAL PARTNERS; SEXUALLY TRANSMITTED DISEASES;

EID: 84866362982     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0b013e3283577e9d     Document Type: Review

References (42)

1. Centers for Disease Control and Prevention. Expedited partner therapy in the management of sexually transmitted diseases: Review and guidance. Atlanta, GA: Department of Health and Human Services, 2006.
2. Steiner KC, Davila V, Kent CK, et al. Field-delivered therapy increases treatment for chlamydia and gonorrhea. Am J Public Health 2003; 93:882-884. (Pubitemid 38480214)
3. Kissinger P, Hogben M. Expedited partner therapy for sexually transmitted infections: an update. Curr Infect Dis Rep 2011; 13:188-195.
4. Schillinger JA, Kissinger P, Calvet H, et al. Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women. Sex Transm Dis 2003; 30:49-56. (Pubitemid 36071086)
5. Golden MR, Whittington WW, Handsfield HH, et al. Impact of expedited sex partner treatment on recurrent or persistent gonorrhea or chlamydial infection: a randomized controlled trial. New Engl J Med 2005; 352:676-685. (Pubitemid 40239215)
6. Kissinger P, Mohammed H, Richardson-Alston G, et al. Patient-delivered partner treatment for male urethritis: a randomized controlled trial. Clin Infect Dis 2005; 41:623-629. (Pubitemid 41170350)
7. Trelle S, Shang A, Nartey L, et al. Improved effectiveness of partner notification for patients with sexually transmitted infections: Systematic review. BMJ 2007; 334:354.
8. Centers for Disease Control and Prevention. Sexually Transmitted Disease treatment guidelines, 2010. MMWR 2010; 59:1-110.
9. Cameron ST, Glasier A, Scott G, et al. Novel interventions to reduce reinfection in women with chlamydia: a randomized controlled trial. Hum Reprod 2009; 24:888-895.
10. Golden MR, Estcourt CS. Barriers to the implementation of expedited partner therapy. Sex Transm Inf 2011; 87:i37-i38.
11. Estcourt C, Sutcliffe L, Cassell J, et al. Can we improve partner notification rates through expedited partner therapy in the UK? Findings from an exploratory trial of Accelerated Partner Therapy (APT). Sex Transm Inf 2012; 88:21-26.
12. Shackleton T, Sutcliffe L, Estcourt C. Is Accelerated Partner Therapy partner notification for sexually transmissible infections acceptable and feasible in general practice? Sex Health 2011; 8:17-22.
13. Gift TL, Kissinger P, Mohammed H, et al. The cost and cost-effectiveness of expedited partner therapy compared with standard partner referral for the treatment of chlamydia or gonorrhea. Sex Transm Dis 2011; 38:1067-1073.
14. Schwebke JR, Desmond RA. A randomized controlled trial of partner notification methods for prevention of trichomoniasis in women. Sex Transm Dis 2010; 37:392-396.
15. Yu YY, Frasure-Williams JA, Dunne EF, et al. Chlamydia partner services for females in California family planning clinics. Sex Transm Dis 2011; 38:913-918.
16. Kerns JL, Jones HE, Pressman EJ, et al. Implementation of expedited partner therapy among women with chlamydia infection at an urban family planning clinic. Sex Transm Dis 2011; 38:722-726.
17. Ames AK, Muvva R, Miazad R, et al. Expedited partner therapy for gonorrhea and chlamydia decreases visits for reinfection among STD clinic patients. Atlanta, GA: National STD Prevention Conference; 2010.
18. Stephens SC, Bernstein KT, Katz MH, et al. The effectiveness of patientdelivered partner therapy and chlamydial and gonococcal reinfection in San Francisco. Sex Transm Dis 2010; 37:525-529.
19. Hodge JG, Pulver A, Hogben M, et al. Expedited partner therapy for sexually transmitted diseases: Assessing the legal environment. Am J Public Health 2008; 98:238-243. (Pubitemid 351317558)
20. Melvin L, Cameron ST, Glasier A, et al. Preferred strategies of men and women for managing chlamydial infection. Brit J ObstetGyn 2009; 116:357-365.
21. Gursahaney PR, Jeong K, Dixon BW, Wiesenfeld HC. Partner notification of sexually transmitted diseases: Practices and preferences. Sex Transm Dis 2011; 38:821-827.
22. McNutt LA, Davis CF, Bednarczyk RA, et al. Alternative approaches to partner notification, diagnosis, and treatment: Pharmacists' perspectives on proposed patient delivered partner therapy in New York State, 2007. Sex Transm Dis 2009; 36:178-184.
23. Shivasankar S, Challenor R. Patient-delivered partner therapy in the UK: what do the professionals think? Int J STD AIDS 2008; 19:437-440.
24. Taylor MM, Collier MG, Winscott MM, et al. Reticence to prescribe: utilization of expedited partner therapy among obstetrics providers in Arizona. Int J STD AIDS 2011; 22:449-452.
25. Davis CF, Cummings M, Coles BF, McNutt LA. Alternative approaches to partner notification, diagnosis, and treatment: Perspectives of New York County health departments, 2007. Sex Transm Dis 2009; 36:185-190.
26. Ito M, Yasuda M, Yokoi S, et al. Remarkable increase in central Japan in 2001-2002 of Neisseria gonorrhoeae isolates with decreased susceptibility to penicillin, tetracycline, oral cephalosporins, and fluoroquinolones. Antimicrob Agents Chemother 2004; 48:3185-3187. (Pubitemid 38989201)
27. Tanaka M, Nakayama H, Tunoe H, et al. A remarkable reduction in the susceptibility of Neisseria gonorrhoeae isolates to cephems and the selection of antibiotic regimens for the single-dose treatment of gonococcal infection in Japan. J Infect Chemother 2002; 8:81-86. (Pubitemid 34456585)
28. Su X, Jiang F, Quimuge, et al. Surveillance of antimicrobial susceptibilities in Neisseria gonorrhoeae in Nanjing, China, 1999-2006. Sex Transm Dis 2007; 34:995-999. (Pubitemid 350158851)
29. Cole MJ, Chisholm SA, Hoffmann S, et al. European surveillance of antimicrobial resistance in Neisseria gonorrhoeae. Sex Transm Dis 2010; 36:427-432.
30. Martin I, Swatzky P, Allen V, et al. Emergence and characterization of Neisseria gonorrhoeae isolates with decreased susceptibilities to ceftriaxone and cefixime in Canada: 2001-2010. Sex Transm Dis 2012; 39:316-323.
31. Centers for Disease Control and Prevention. Cephalosporin susceptibility among Neisseria gonorrhoeae isolates: United States, 2000-2010. MMWR 2011; 60:873-877.
32. Deguchi T, Yasuda M, Yokoi S, et al. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J Infect Chemother 2003; 9:35-39. (Pubitemid 36504368)
33. Yokoi S, Deguchi T,Ozawa T, et al. Threat to cefixime treatment for gonorrhea. Emerg Infect Dis 2007; 13:1275-1277.
34. Unemo M, Golparian D, Stary A, Eigentler A. First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoeae treatment failure in Austria, 2011. Eurosurv 2011; 16.
35. Unemo M, Golparian D, Syversen G, et al. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Eurosurv 2010; 15.
36. Unemo M, Golparian D, Nicholas R, et al. High-level cefixime-and ceftriaxoneresistant N. gonorrhoeae in Europe (France): novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012; 56:1273-1280.
37. Ison CA, Hussey J, Sankar KN, et al. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Eurosurv 2011; 16.
38. Forsyth S, Penney P, Rooney G. Cefixime-resistant Neisseria gonorrhoeae in the UK: a time to reflect on practice and recommendations. Int J STD AIDS 2011; 22:296-297.
39. CDC. Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral Cephalosporins No Longer a Recommended Treatment for Gonococcal Infections. MMWR 2012; 61:590-594.
40. Katz AR, Komeya AY, Soge OO, et al. Neisseria gonorrhoeae with high-level resistance to azithromycin: case report of the first isolate identified in the United States. Clin Infect Dis 2012; 54:841-843.
41. Chisholm SA, Neal TJ, Alawattegama AB, et al. Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. J Antimicrob Chemother 2009; 64:353-358.
42. Wilson TE, Hogben M, Malka E, et al. Reducing sexually transmitted infection rates by improving patient referral for treatment: a randomized, controlled trial. Am J Public Health 2009; 99 (suppl):S104-S110.